457 related articles for article (PubMed ID: 23811235)
41. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M
Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719
[TBL] [Abstract][Full Text] [Related]
42. The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia.
Georgoulia PS; Todde G; Bjelic S; Friedman R
Biochim Biophys Acta Gen Subj; 2019 Apr; 1863(4):732-741. PubMed ID: 30684523
[TBL] [Abstract][Full Text] [Related]
43. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
[TBL] [Abstract][Full Text] [Related]
44. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
La Pietra V; Sartini S; Botta L; Antonelli A; Ferrari SM; Fallahi P; Moriconi A; Coviello V; Quattrini L; Ke YY; Hsing-Pang H; Da Settimo F; Novellino E; La Motta C; Marinelli L
Eur J Med Chem; 2018 Apr; 150():491-505. PubMed ID: 29549836
[TBL] [Abstract][Full Text] [Related]
45. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
Terzyan SS; Shen T; Liu X; Huang Q; Teng P; Zhou M; Hilberg F; Cai J; Mooers BHM; Wu J
J Biol Chem; 2019 Jul; 294(27):10428-10437. PubMed ID: 31118272
[TBL] [Abstract][Full Text] [Related]
46. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
Plenker D; Riedel M; Brägelmann J; Dammert MA; Chauhan R; Knowles PP; Lorenz C; Keul M; Bührmann M; Pagel O; Tischler V; Scheel AH; Schütte D; Song Y; Stark J; Mrugalla F; Alber Y; Richters A; Engel J; Leenders F; Heuckmann JM; Wolf J; Diebold J; Pall G; Peifer M; Aerts M; Gevaert K; Zahedi RP; Buettner R; Shokat KM; McDonald NQ; Kast SM; Gautschi O; Thomas RK; Sos ML
Sci Transl Med; 2017 Jun; 9(394):. PubMed ID: 28615362
[TBL] [Abstract][Full Text] [Related]
47. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
[TBL] [Abstract][Full Text] [Related]
48. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
49. A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.
Sala E; Mologni L; Cazzaniga S; Papinutto E; Gambacorti-Passerini C
Int J Biol Macromol; 2006 Aug; 39(1-3):60-5. PubMed ID: 16490247
[TBL] [Abstract][Full Text] [Related]
50. In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.
George Priya Doss C; Rajith B; Chakraboty C; Balaji V; Magesh R; Gowthami B; Menon S; Swati M; Trivedi M; Paul J; Vasan R; Das M
Mol Biosyst; 2014 Mar; 10(3):421-36. PubMed ID: 24336963
[TBL] [Abstract][Full Text] [Related]
51. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
[TBL] [Abstract][Full Text] [Related]
52. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
[TBL] [Abstract][Full Text] [Related]
53. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
[TBL] [Abstract][Full Text] [Related]
54. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
55. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
56. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.
Neelakantan P; Marin D; Laffan M; Goldman J; Apperley J; Milojkovic D
Haematologica; 2012 Sep; 97(9):1444. PubMed ID: 22532521
[No Abstract] [Full Text] [Related]
57. Management of medullary thyroid cancer.
Ball DW
Minerva Endocrinol; 2011 Mar; 36(1):87-98. PubMed ID: 21460789
[TBL] [Abstract][Full Text] [Related]
58. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
Zhou T; Commodore L; Huang WS; Wang Y; Sawyer TK; Shakespeare WC; Clackson T; Zhu X; Dalgarno DC
Chem Biol Drug Des; 2010 Jan; 75(1):18-28. PubMed ID: 19895503
[TBL] [Abstract][Full Text] [Related]
59. Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.
Gujral TS; Mulligan LM
Ann N Y Acad Sci; 2006 Aug; 1073():234-40. PubMed ID: 17102091
[TBL] [Abstract][Full Text] [Related]
60. RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.
Asai N; Jijiwa M; Enomoto A; Kawai K; Maeda K; Ichiahara M; Murakumo Y; Takahashi M
Pathol Int; 2006 Apr; 56(4):164-72. PubMed ID: 16634961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
